Metagenomi Therapeutics, Inc.·4

Jun 11, 1:37 PM ET

Eckhardt Juergen 4

Research Summary

AI-generated summary

Updated

Metagenomi (MGX) Director Juergen Eckhardt Receives Equity Award

What Happened
Director Juergen Eckhardt was granted a derivative equity award for 21,000 shares on 2026-06-09. The filing lists the acquisition price as $0.00 (total value $0 on grant). This was an award/grant (code A), not an open-market purchase or sale.

Key Details

  • Transaction date: 2026-06-09; Filing date: 2026-06-11 (appears timely — within the Form 4 two-business-day window).
  • Instrument and amount: 21,000 shares reported as a derivative award at $0.00 per share.
  • Shares owned after transaction: Not specified in the provided excerpt of the Form 4 — check the full filing for post-transaction beneficial ownership.
  • Footnote (vesting): The award vests upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company’s 2027 annual meeting of stockholders, subject to continued service.
  • Transaction code: A = Grant/Award.

Context
This is a standard director equity award subject to a vesting schedule; the shares are not immediately exercisable/owned unless and until vesting conditions are met. Grants to directors are common and reflect compensation, not necessarily a buy/sell signal. Check the full Form 4 for details on total holdings and any additional terms.